DelveInsight’s report, “Natural Killer Cells Therapies- Competitive Landscape, Technology and Pipeline Analysis, 2017”, emphasizes on the currently active NK cell therapy products and NK cell augmenters in research and development.
The report covers 20+ companies, which are active in this field with 40+ products and many different technologies. This report covers NK cell based therapies and drugs that augment (enhance or activate) the NK cells. The report provides in-depth analysis on the Natural Killer Cell based therapies profiles along with the augmenting therapies covering their pre-clinical and clinical studies, collaborations details and deal values, technologies and targeted antigens. The report provides the NK Cell based therapies licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis.
Reports Highlights:
NK cell Therapy Pipeline scenario which includes NK cell therapies and NK cell augmenting therapies.
Collaborations & partnering deals
Current Prominent Research Areas and Key Players
Pipeline product profiles NK Cell therapy Technologies and NK cell Augmenting Therapies
Licensing opportunities
Market Drivers and Barriers
Scope
Overview of the global NK cell therapy and NK cell augmenting therapies pipeline scenario, products and associated companies information
Coverage of global NK cell therapies and drugs that enhance the activity of NK under development
Competitive landscape of products for key players and related indications
Coverage of licensors, collaborators and development partners, deal terms and deal values estimation
Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
Highlights of licensing & collaboration opportunities and funding details
Highlights of latest NK cell therapy technologies and NK cell augmenting therapies and innovative companies
Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis
'
Report Introduction 1
Reports Highlights 1
Scope 1
Executive Summary 12
Natural Killer Cells Therapy Overview 13
Leading Companies with NEXT Generation Technologies 16
Market Drivers 17
Market Barriers 19
SWOT Analysis 20
Natural Killer Cells Based Therapies 21
Natural Killer Cells Based Therapies and Targets 22
NK Cells Based Therapy Collaborations 24
Collaborations and Deal Year 24
Collaborations and Deal value 24
Licensing Agreement for Future Developments 25
Institutes involved in NK cells based therapies 26
NK Cells Based Therapies and Technologies 28
Clinical trials & Completion Year 30
Phase II Trials 30
Phase I Trials 31
Pipeline Therapeutics for Natural Killer Cells Based Therapies 32
Therapeutics under Development by Companies 33
Mid Stage Products (Phase II) 34
Comparative Analysis 34
Early Stage Products (Phase I and IND) 47
Comparative Analysis 47
Pre-Clinical Products 58
Comparative Analysis 58
Therapeutic Assessment of Natural Killer Cell Therapies 99
Assessment by Monotherapy Products 99
Assessment by Combination Products 100
Assessment by Route of Administration 101
Assessment by Stage and Route of Administration 102
Assessment by Molecule Type 103
Assessment by Stage and Molecule Type 104
Assessment by Domain 105
Assessment by Stage and Domain 106
Natural Killer Cell Augmenters 107
Targets of Natural Killer Cells Augmenters and Their Analysis 108
NK Cells Augmenters Based Therapy Collaborations
Collaborations and Deal Year 109
Collaborations and Deal value 110
Licensing Agreement for future development of NK Cell Augmenters Therapy 111
Financing details of NK cells augmenters based therapies 113
Companies received Grants for NK cells augmenters based therapies
Designation
Institutes involved in NK Cells Augmenters Based Therapies
NK Cells Augmenters Based Therapies and Technologies
Clinical trials & Completion Year
Phase III Trials
Phase II Trials
Phase I Trials
Pipeline Therapeutics for Natural Killer Cells Augmenters(Enhancers & Activators)
Therapeutics under Development by Companies
NK Cells Enhancers
NK Cells Activators
Natural Killer Cell Enhancers
Late Stage Products (Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre –clinical Products
Comparative Analysis
Natural Killer Cells Activators
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre –clinical Products
Comparative Analysis
Therapeutic Assessment of Natural Killer Cell Augmenters (Enhancers & Activators)
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Assessment by Domain
Assessment by Stage and Domain
Appendix
Report Methodology
DelveInsight Consulting Services
About DelveInsight
Contact Us
Disclaimer
Table 1:SWOT analysis of NK Cells Based Therapies& Augmenters, 2017
Table 2: Targets and Number of Products
Table 3:Natural Killer Cells based therapies -Target Antigens and Companies
Table 4:Collaboration and Deal Values for NK cell therapy, 2017
Table 5:Licensing Agreement for future development of NK Cell based Therapies, 2017
Table 6: Institute involved in NK Cells based Therapies, 2017
Table 7 : Companies and their technologies for NK Cells Based Therapies, 2017
Table 8: Natural Killer Cell based therapies-Study Completion Date of Phase II Drugs, 2017
Table 9: Natural Killer Cell based therapies-Study Completion Date of Phase I Drugs, 2017
Table 10:Number of Products Under Development for Natural Killer Cells Therapies, 2017
Table 11: Number of Products under development by Companies, 2017
Table 12: Mid Stage Products (Phase II), 2017
Table 13: Early Stage Products (Phase I), 2017
Table 14: Pre-Clinical Products, 2017
Table 15: Assessment by Monotherapy Products, 2017
Table 16:Assessment by Combination Products, 2017
Table 17: Assessment by Route Of Administration, 2017
Table 18:Assessment by Stage and Route Of Administration, 2017
Table 19: Assessment by Molecule Type, 2017
Table 20: Assessment by Stage and Molecule Type, 2017
Table 21:Assessment by Stage of development and Domain, 2017
Table 22:Assessmentby Stage of development and Domain, 2017
Table 23:Targets and Number of Products
Table 24:Natural Killer Cells Augmenters based therapies -Target Antigens and Companies
Table 25:Collaboration and Deal Values for NK cell Augmenters therapy, 2017
Table 26: Licensing Agreement for future development of NK Cell Augmenters Therapy, 2017
Table 27:Companies of NK cells augmenters based therapies financing for future developments, 2017
Table 28:Companies of NK cells Augmenters Received Grants, 2017
Table 29: Analysis of Natural Killer Cells Augmenters On The Basis of Designation, 2017
Table 30: Institute involved in NK Cells Augmenters, 2017
Table 32: Natural Killer Cell Augmenters based therapies-Study Completion Date of Phase III Drugs, 2017
Table 33: Natural Killer Cell Augmenters based therapies-Study Completion Date of Phase II Drugs, 2017
Table 34: Natural Killer Cell Augmenters based therapies-Study Completion Date of Phase I Drugs, 2017
Table 35:Number of Products Under Development for Natural Killer Cells Augmenters(Enhancers & Activators), 2017
Table 36: Number of Products under development by Companies, 2017
Table 37: Number of Products under development by Companies, 2017
Table 38: Late Stage Products (Phase III), 2017
Table 39: Mid Stage Products (Phase II), 2017
Table 40: Early Stage Products (Phase I), 2017
Table 41: Pre –clinical Products (Phase I), 2017
Table 42: Mid Stage Products (Phase II), 2017
Table 43: Early Stage Products (Phase I), 2017
Table 44: Pre –clinical Products (Phase I), 2017
Table 45: Assessment by Monotherapy Products, 2017
Table 46: Assessment by Route Of Administration, 2017
Table 47:Assessment by Stage and Route Of Administration, 2017 200
Table 48: Assessment by Molecule Type, 2017
Table 49: Assessment by Stage and Molecule Type, 2017
Table 50:Assessment by Stage of development and Domain, 2017
Table 51:Assessmentby Stage of development and Domain, 2017
